BR0112475B1 - N-óxido de derivados 4-fenil-piridina como antagonista de receptor nk1, seu medicamento, seu processo de preparação e seus usos - Google Patents

N-óxido de derivados 4-fenil-piridina como antagonista de receptor nk1, seu medicamento, seu processo de preparação e seus usos

Info

Publication number: BR0112475B1
Authority: BR; Brazil
Prior art keywords: phenyl; oxide; preparation process; medicinal product; pyridine derivatives
Prior art date: 2000-07-14

Application number

BRPI0112475-7B1A

Other languages

English (en)

Other versions

BRPI0112475B8 (pt

BR0112475A (pt

Inventor

Torsten Hoffmann

Sonia Maria Poli

Patrick Schnider

Andrew Sleight

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-14

Filing date

2001-07-09

Publication date

2013-10-15

2001-07-09 Application filed filed Critical

2003-07-29 Publication of BR0112475A publication Critical patent/BR0112475A/pt

2013-10-15 Publication of BR0112475B1 publication Critical patent/BR0112475B1/pt

2021-05-25 Publication of BRPI0112475B8 publication Critical patent/BRPI0112475B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

BRPI0112475A 2000-07-14 2001-07-09 n-óxido de derivados 4-fenil-piridina como antagonista de receptor nk1, seu medicamento, seu processo de preparação e seus usos BRPI0112475B8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00115287		2000-07-14
PCT/EP2001/007850 WO2002006236A1 (en)	2000-07-14	2001-07-09	N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives

Publications (3)

Publication Number	Publication Date
BR0112475A BR0112475A (pt)	2003-07-29
BR0112475B1 true BR0112475B1 (pt)	2013-10-15
BRPI0112475B8 BRPI0112475B8 (pt)	2021-05-25

Family

ID=8169262

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0112475A BRPI0112475B8 (pt)	2000-07-14	2001-07-09	n-óxido de derivados 4-fenil-piridina como antagonista de receptor nk1, seu medicamento, seu processo de preparação e seus usos

Country Status (38)

Country	Link
US (4)	US6593472B2 (pt)
EP (1)	EP1303490B1 (pt)
JP (1)	JP3950044B2 (pt)
KR (1)	KR100501608B1 (pt)
CN (1)	CN1178917C (pt)
AR (1)	AR029717A1 (pt)
AT (1)	ATE400556T1 (pt)
AU (1)	AU7061901A (pt)
BR (1)	BRPI0112475B8 (pt)
CA (1)	CA2415890C (pt)
CY (1)	CY1108557T1 (pt)
CZ (1)	CZ303639B6 (pt)
DE (1)	DE60134749D1 (pt)
DK (1)	DK1303490T3 (pt)
EC (1)	ECSP034431A (pt)
EG (1)	EG24968A (pt)
ES (1)	ES2309075T3 (pt)
GT (1)	GT200100137A (pt)
HR (1)	HRP20030003B1 (pt)
HU (1)	HU230316B1 (pt)
IL (2)	IL153834A0 (pt)
JO (1)	JO2372B1 (pt)
MA (1)	MA26929A1 (pt)
ME (1)	ME01311B (pt)
MX (1)	MXPA03000366A (pt)
MY (1)	MY154976A (pt)
NO (1)	NO324700B1 (pt)
NZ (1)	NZ523273A (pt)
PA (1)	PA8522001A1 (pt)
PE (1)	PE20020272A1 (pt)
PL (1)	PL205207B1 (pt)
PT (1)	PT1303490E (pt)
RS (1)	RS50932B (pt)
RU (1)	RU2266284C2 (pt)
SI (1)	SI1303490T1 (pt)
UY (1)	UY26839A1 (pt)
WO (1)	WO2002006236A1 (pt)
ZA (1)	ZA200210207B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1103545T1 (en) *	1999-11-29	2004-02-29	F. Hoffmann-La Roche Ag	2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
NZ523273A (en) *	2000-07-14	2004-08-27	F	N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) *	2000-07-24	2007-09-21	Hoffmann La Roche	4-phenyl-pyridine derivatives
CA2444395C (en) *	2001-04-23	2010-12-21	F. Hoffmann-La Roche Ag	Use of nk-1 receptor antagonists against benign prostatic hyperplasia
DE602004008631T2 (de) *	2003-07-03	2008-07-10	F. Hoffmann-La Roche Ag	Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
CA2572645C (en)	2004-07-06	2011-01-18	F. Hoffmann-La Roche Ag	Process for preparing carboxamide derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
US20060030600A1 (en) *	2004-08-06	2006-02-09	Patrick Schnider	Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
WO2006089674A2 (en)	2005-02-25	2006-08-31	F.Hoffmann-La Roche Ag	Tablets with improved drug substance dispersibility
EP1863767B1 (en) *	2005-03-23	2009-03-11	F. Hoffmann-Roche AG	Metabolites for nk-i antagonists for emesis
JP2008280248A (ja) *	2005-11-02	2008-11-20	Eisai R & D Management Co Ltd	アルツハイマー型痴呆症治療薬塩酸ドネペジルのプロドラッグ
WO2008090114A1 (en)	2007-01-24	2008-07-31	Glaxo Group Limited	Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0808747D0 (en)	2008-05-14	2008-06-18	Glaxo Wellcome Mfg Pte Ltd	Novel compounds
US8966414B2 (en)	2009-05-29	2015-02-24	Cypress Semiconductor Corporation	Implementing a circuit using an integrated circuit including parametric analog elements
US9858367B1 (en) *	2009-08-31	2018-01-02	Cypress Semiconductor Corporation	Integrated circuit including parametric analog elements
EP2722045B1 (en)	2009-11-18	2016-07-06	Helsinn Healthcare SA	Compositions for treating centrally mediated nausea and vomiting
LT2722045T (lt)	2009-11-18	2016-09-26	Helsinn Healthcare Sa	Kompozicija skirta gydyti centralizuotai kontroliuojamą pykinimą ir vėmimą
JP2014530249A (ja)	2011-10-18	2014-11-17	ヘルシンヘルスケアソシエテアノニム	ネツピタントおよびパロノセトロンの治療学的組合せ
US8426450B1 (en) *	2011-11-29	2013-04-23	Helsinn Healthcare Sa	Substituted 4-phenyl pyridines having anti-emetic effect
HRP20171665T1 (hr)	2011-12-28	2017-12-15	Global Blood Therapeutics, Inc.	Supstituirani spojevi benzaldehida i metode za njihovu primjenu u povećanju oksigenacije tkiva
HK1203412A1 (en)	2011-12-28	2015-10-30	Global Blood Therapeutics, Inc.	Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9802900B2 (en)	2013-03-15	2017-10-31	Global Blood Therapeutics, Inc.	Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en)	2013-03-15	2016-08-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
PE20161035A1 (es)	2013-03-15	2016-11-13	Global Blood Therapeutics Inc	Compuestos y usos de estos para la modulacion de la hemoglobina
EP2970308B1 (en) *	2013-03-15	2021-07-14	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
CA2902711C (en)	2013-03-15	2021-07-06	Global Blood Therapeutics, Inc.	Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
US10100043B2 (en)	2013-03-15	2018-10-16	Global Blood Therapeutics, Inc.	Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en)	2013-03-15	2017-03-28	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en)	2013-03-15	2019-04-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
ES2671418T3 (es)	2013-11-08	2018-06-06	Kissei Pharmaceutical Co., Ltd.	Derivado de carboximetilpiperidina
EA201992707A1 (ru)	2013-11-18	2020-06-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
US10350098B2 (en) *	2013-12-20	2019-07-16	Volcano Corporation	Devices and methods for controlled endoluminal filter deployment
AP2016009261A0 (en)	2014-02-07	2016-06-30	Global Blood Therapeutics Inc	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI649307B (zh)	2014-05-07	2019-02-01	日商橘生藥品工業股份有限公司	Cyclohexylpyridine derivative
CN106588899B (zh) *	2015-10-15	2019-11-15	江苏恒瑞医药股份有限公司	吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用
DK3383392T3 (da)	2015-12-04	2025-08-18	Global Blood Therapeutics Inc	Doseringsskema for 2.HYDROXY.6.((2.(1.ISOPROPYL.1H.PYRAZOL.5.YL)PYRIDIN.3.YL)METHOXY)BENZALDEHYD
TWI752307B (zh)	2016-05-12	2022-01-11	美商全球血液治療公司	新穎化合物及製造化合物之方法
TW202332423A (zh)	2016-10-12	2023-08-16	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
IL312486B2 (en)	2017-04-10	2025-05-01	Chase Therapeutics Corp	NK1 antagonist combination and method for treating synucleinopathies
KR20250069704A (ko)	2017-06-30	2025-05-19	체이스 테라퓨틱스 코포레이션	우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
US11014884B2 (en)	2018-10-01	2021-05-25	Global Blood Therapeutics, Inc.	Modulators of hemoglobin
US12479816B2 (en)	2019-02-08	2025-11-25	University of Pittsburgh—of the Commonwealth System of Higher Education	20-HETE formation inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS56106286A (en)	1980-01-28	1981-08-24	Nippon Musical Instruments Mfg	Electronic musical instrument
EP0103545A3 (en)	1982-09-13	1984-10-03	Arc Technologies Systems, Ltd.	Electrode for arc furnaces
IL111960A (en)	1993-12-17	1999-12-22	Merck & Co Inc	Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
NZ277839A (en)	1993-12-29	1998-01-26	Merck Sharp & Dohme	Substituted morpholine derivatives, preparation and pharmaceutical compositions thereof
TW385308B (en)	1994-03-04	2000-03-21	Merck & Co Inc	Prodrugs of morpholine tachykinin receptor antagonists
DE19627431A1 (de) *	1996-07-08	1998-01-15	Bayer Ag	Heterocyclisch kondensierte Pyridine
AR008789A1 (es) *	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
US5972938A (en)	1997-12-01	1999-10-26	Merck & Co., Inc.	Method for treating or preventing psychoimmunological disorders
JP4068305B2 (ja) *	1999-02-24	2008-03-26	エフ．ホフマン−ラロシュアーゲー	３−フェニルピリジン誘導体、およびそのｎｋ−１受容体拮抗薬としての用途
DK1394150T3 (da)	1999-02-24	2011-03-21	Hoffmann La Roche	4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
RU2238264C2 (ru) *	1999-02-24	2004-10-20	Ф.Хоффманн-Ля Рош Аг	Производные бензола или пиридина и фармацевтическая композиция на их основе
SI1103545T1 (en) *	1999-11-29	2004-02-29	F. Hoffmann-La Roche Ag	2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
NZ523273A (en) *	2000-07-14	2004-08-27	F	N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
US20030083345A1 (en) *	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury

2001
- 2001-07-09 NZ NZ523273A patent/NZ523273A/en not_active IP Right Cessation
- 2001-07-09 CN CNB018128246A patent/CN1178917C/zh not_active Expired - Lifetime
- 2001-07-09 EP EP01949475A patent/EP1303490B1/en not_active Expired - Lifetime
- 2001-07-09 RU RU2003102612/04A patent/RU2266284C2/ru active
- 2001-07-09 PL PL365684A patent/PL205207B1/pl unknown
- 2001-07-09 PT PT01949475T patent/PT1303490E/pt unknown
- 2001-07-09 IL IL15383401A patent/IL153834A0/xx unknown
- 2001-07-09 MX MXPA03000366A patent/MXPA03000366A/es active IP Right Grant
- 2001-07-09 ME MEP-2008-770A patent/ME01311B/me unknown
- 2001-07-09 BR BRPI0112475A patent/BRPI0112475B8/pt not_active IP Right Cessation
- 2001-07-09 AT AT01949475T patent/ATE400556T1/de active
- 2001-07-09 DK DK01949475T patent/DK1303490T3/da active
- 2001-07-09 HR HR20030003A patent/HRP20030003B1/xx not_active IP Right Cessation
- 2001-07-09 HU HU0301311A patent/HU230316B1/hu unknown
- 2001-07-09 KR KR10-2003-7000476A patent/KR100501608B1/ko not_active Expired - Lifetime
- 2001-07-09 ES ES01949475T patent/ES2309075T3/es not_active Expired - Lifetime
- 2001-07-09 DE DE60134749T patent/DE60134749D1/de not_active Expired - Lifetime
- 2001-07-09 AU AU7061901A patent/AU7061901A/xx active Pending
- 2001-07-09 CA CA002415890A patent/CA2415890C/en not_active Expired - Lifetime
- 2001-07-09 CZ CZ20030428A patent/CZ303639B6/cs not_active IP Right Cessation
- 2001-07-09 RS YUP-6/03A patent/RS50932B/sr unknown
- 2001-07-09 JP JP2002512140A patent/JP3950044B2/ja not_active Expired - Lifetime
- 2001-07-09 WO PCT/EP2001/007850 patent/WO2002006236A1/en not_active Ceased
- 2001-07-09 SI SI200130848T patent/SI1303490T1/sl unknown
- 2001-07-10 JO JO2001106A patent/JO2372B1/en active
- 2001-07-11 EG EG2001070771A patent/EG24968A/xx active
- 2001-07-11 PA PA20018522001A patent/PA8522001A1/es unknown
- 2001-07-12 MY MYPI20013310A patent/MY154976A/en unknown
- 2001-07-12 US US09/904,059 patent/US6593472B2/en not_active Expired - Lifetime
- 2001-07-12 GT GT200100137A patent/GT200100137A/es unknown
- 2001-07-13 AR ARP010103335A patent/AR029717A1/es active IP Right Grant
- 2001-07-13 UY UY26839A patent/UY26839A1/es not_active IP Right Cessation
- 2001-07-13 PE PE2001000704A patent/PE20020272A1/es active IP Right Grant
2002
- 2002-12-17 ZA ZA200210207A patent/ZA200210207B/en unknown
2003
- 2003-01-07 IL IL153834A patent/IL153834A/en active IP Right Grant
- 2003-01-07 US US10/337,543 patent/US6747026B2/en not_active Expired - Lifetime
- 2003-01-13 NO NO20030154A patent/NO324700B1/no not_active IP Right Cessation
- 2003-01-13 MA MA26997A patent/MA26929A1/fr unknown
- 2003-01-14 EC EC2003004431A patent/ECSP034431A/es unknown
- 2003-07-09 US US10/616,276 patent/US6897226B2/en not_active Expired - Lifetime
- 2003-08-21 US US10/645,895 patent/US6806370B2/en not_active Expired - Lifetime
2008
- 2008-10-07 CY CY20081101108T patent/CY1108557T1/el unknown

Also Published As

Publication number	Publication date
EP1303490A1 (en)	2003-04-23
NO20030154D0 (no)	2003-01-13
DK1303490T3 (da)	2008-08-25
HU230316B1 (hu)	2016-01-28
ECSP034431A (es)	2003-03-10
EP1303490B1 (en)	2008-07-09
JO2372B1 (en)	2006-12-12
SI1303490T1 (sl)	2008-10-31
HRP20030003B1 (en)	2011-01-31
MY154976A (en)	2015-08-28
IL153834A0 (en)	2003-07-31
CY1108557T1 (el)	2014-04-09
HRP20030003A2 (en)	2003-02-28
ZA200210207B (en)	2004-03-17
PA8522001A1 (es)	2002-04-25
US6897226B2 (en)	2005-05-24
PL205207B1 (pl)	2010-03-31
ES2309075T3 (es)	2008-12-16
AR029717A1 (es)	2003-07-10
CA2415890C (en)	2009-04-07
RS50932B (sr)	2010-08-31
KR20030015387A (ko)	2003-02-20
MA26929A1 (fr)	2004-12-20
US6806370B2 (en)	2004-10-19
US20040048901A1 (en)	2004-03-11
CZ303639B6 (cs)	2013-01-23
NO324700B1 (no)	2007-12-03
DE60134749D1 (de)	2008-08-21
ATE400556T1 (de)	2008-07-15
US20020045642A1 (en)	2002-04-18
AU7061901A (en)	2002-01-30
HUP0301311A2 (hu)	2003-08-28
NZ523273A (en)	2004-08-27
US6747026B2 (en)	2004-06-08
KR100501608B1 (ko)	2005-07-18
US20040014793A1 (en)	2004-01-22
BRPI0112475B8 (pt)	2021-05-25
JP3950044B2 (ja)	2007-07-25
IL153834A (en)	2008-11-03
NO20030154L (no)	2003-01-13
MXPA03000366A (es)	2003-05-27
US6593472B2 (en)	2003-07-15
CN1178917C (zh)	2004-12-08
CA2415890A1 (en)	2002-01-24
US20030149039A1 (en)	2003-08-07
UY26839A1 (es)	2002-01-31
BR0112475A (pt)	2003-07-29
EG24968A (en)	2011-03-14
WO2002006236A1 (en)	2002-01-24
CN1441782A (zh)	2003-09-10
PE20020272A1 (es)	2002-04-16
JP2004504301A (ja)	2004-02-12
PL365684A1 (en)	2005-01-10
RU2266284C2 (ru)	2005-12-20
ME01311B (me)	2013-12-20
PT1303490E (pt)	2008-09-04
HK1058198A1 (en)	2004-05-07
YU603A (sh)	2006-01-16
GT200100137A (es)	2002-05-16

Publication	Publication Date	Title
BR0112475B1 (pt)	2013-10-15	N-óxido de derivados 4-fenil-piridina como antagonista de receptor nk1, seu medicamento, seu processo de preparação e seus usos
SI1325001T1 (sl)	2004-08-31	Antiholinergična sredstva, uporabljiva kot zdravila, in postopek za njihovo pripravo
HUP0301671A3 (en)	2010-03-29	4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
BR0116505A (pt)	2004-02-03	Compostos ou um sal deste farmaceuticamente aceitável, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios onde um antagonista de um receptor de orexina humano é requerido, e, processo para a fabricação de composições farmacêuticas para o tratamento de distúrbios associados com o papel da orexina, especialmente da obesidade e distúrbios do sono
IL152418A0 (en)	2003-05-29	Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
HUP0300138A3 (en)	2003-06-30	Cyclic amine derivatives as ccr5 antagonists, their production and use and pharmaceutical compositions containing them
UY24560A1 (es)	2000-12-29	Derivados arilos de la pirimidina útiles como antagonistas 5ht2b selectivos
PT101038A (pt)	1994-02-28	Derivados de indano e indeno, seu processo de preparacao, composicoes farmaceuticas e seu uso como antagonistas do receptor de endotelina
BR0112711A (pt)	2003-05-20	Derivados de heteroarila e seus usos como medicamentos
EE05001B1 (et)	2008-04-15	Heterotsüklilised ühendid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis
WO2000064441A3 (en)	2001-06-14	Compound for use as a medicament for treatment of disorders involving bronchocontraction
BR0010061A (pt)	2003-02-25	Tratamento de fibrose por antagonista de il-13 e cadeias de receptor il-13
HUP0204410A3 (en)	2003-07-28	Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use
AU5914201A (en)	2001-11-07	Intrathecal administration of rituximab for treatment of central nervous system lymphomas
HUP0401047A3 (en)	2007-12-28	Triazolo[4,5-d]pyrimidine derivatives, their use as purinergic receptor antagonist and pharmaceutical compositions containing same
EE05248B1 (et)	2009-12-15	N-(hetero(arl)asendatud spiro(asa)tskloheksaankarboksamiidi derivaadid, protsess nende valmistamiseks ja kasutamiseks
FR2809732B1 (fr)	2002-07-19	DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE
HUP0300052A3 (en)	2004-03-01	Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists, process for their preparation and pharmaceutical compositions containing them
EE200300254A (et)	2003-12-15	Heterotsüklilised ühendid, millel on antibakteriaalne toime, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
DE60203797D1 (de)	2005-05-25	Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
FR2790474B1 (fr)	2001-04-06	Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
YU74901A (sh)	2004-07-15	Upotreba antagonista subjedinica alfa-4 integrina za pripremanje farmaceutskog preparata za tretiranje fibroze
FR2832712B1 (fr)	2004-02-13	Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
FR2804430B1 (fr)	2002-03-22	Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
WO2006065755A3 (en)	2006-10-12	Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists

Legal Events

Date	Code	Title	Description
2011-02-15	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2011-02-15	B15K	Others concerning applications: alteration of classification	Free format text: ALTERADA DA INT.CL: C07D 213/76, C07D 213/82, C07D 401/04, A61K 31/44, A61P 25/22, A61P 25/24 Ipc: C07D 213/82 (2011.01), C07D 213/75 (2011.01), C07D
2011-07-05	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2012-01-31	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2013-02-05	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2013-08-20	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2013-09-10	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2013-10-15	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/10/2013, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/07/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2023-05-09	B21A	Patent or certificate of addition expired [chapter 21.1 patent gazette]	Free format text: PATENTE EXTINTA EM 09/07/2021